GHRH and non-Hodgkin lymphoma: Previous discoveries featuring the presence of GHRH mRNA and peptides in immune cells, coupled with successful in-vitro and in-vivo attempts against experimental models of non-Hodgkin’s Lymphoma using earlier GHRH-Ants [26] prompted the investigation of newer, more potent GHRH-Ants for treating AML, particularly MIA-602 [27].